Biopharma | January 11, 2026
Prokaryotics and Basilea team up to tackle deadly fungal infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
Subscribe To Our Newsletter & Stay Updated
